FDA ApprovalThe FDA's sNDA approval for leniolisib as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) highlights a significant advancement for Pharming Group Nv.
Financial PerformancePharming announced 2Q25 financial results, posting EPS of $0.006 compared to an estimate of ($0.025), with total revenue for the quarter at $93.2 million vs. an estimate of $83.26 million.
Market ExpansionExpanding leniolisib into the pediatric population addresses an unmet medical need and represents a substantial market opportunity.